# Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

> **NCT03878199** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Essential Thrombocythemia
- Myelofibrosis
- Myeloproliferative Neoplasm
- Polycythemia Vera
- Secondary Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03878199
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-20
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878199, "Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03878199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*